Effect of Insulin Staging in the Context of Pharmaceutical Care on Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

Official title:

The Impact of Insulin Staging in the Context of Pharmaceutical Care on Patients With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05244200
• Other study ID #: College of Pharmacy/ UoS
• Status: Recruiting
• Phase: N/A
• Start date: January 20, 2022
• Est. completion date: November 1, 2022

Study information

• Verified date: February 2022
• Source: University of Sulaimani
• Contact: Kawa Obeid, PhD
• Phone: 009647501112412
• Email: kawa.uobaed[@]univsul.edu.iq
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. Current challenges in diabetes management include: (1) optimizing the use of currently available therapies to ensure adequate glycemic control and to reduce complications; (2) educating patients on diabetes self-management; (3) improving patient adherence to lifestyle and pharmacologic interventions; ; and (4) reducing barriers to the early use of insulin. In this research, the impact of pharmaceutical care and Insulin staging will be evaluated in patients with type 2 diabetes to overcome this challenges. The concept of "pharmaceutical care" was first introduced by Helper and Strand in 1990, pushing for the transformation of the Pharmacy profession from "product-focused" to "patient-centric". Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of the disease, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.

Description:

• In 2018, 34.2 million Americans, or 10.5% of the population, had diabetes.

• Of the 34.2 million adults with diabetes, 26.8 million were diagnosed, and 7.3 million were undiagnosed

• The percentage of Americans age 65 and older remains high, at 26.8%, or 14.3 million seniors (diagnosed and undiagnosed).

• Diabetes Mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism.

• It results from defects in insulin secretion, insulin sensitivity, or both. Chronic microvascular, macrovascular, and neuropathic complications may ensue .

• One of the challenges facing the management of T2DM is the lack of an established guideline for Insulin administration in most of the communities.

• Considering the slogan of clinical pharmacy: safe, cost-effectiveness of medication, there are many Insulin products available and often doctors get confused on Choosing the right drug for the right patient.

• The hypothesis of this study is that clinical pharmacist Intervention through applying Pharmaceutical care and insulin staging has significant impact on quality of life and therapeutic outcomes of patients with Type II Diabetes With the end stage management protocol, while the null hypothesis states that there is no correlation between clinical pharmacist intervention with patient's quality of life and therapeutic outcomes.

• Study design: two-arm randomized, selective control trial.

• Interventions: Insulin Staging in the context of Pharmaceutical Care.

• Number of participants = 100.

• Number of groups = 2 groups each of 50 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 1, 2022
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• T2DM patients.

• Patients must be on insulin therapy

• Willing to participate in the study

Exclusion Criteria:

• T1DM

• T2DM patients whose not on insulin therapy

• Patients that have disabilities that interfere with compliances towards medications

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Other:
• Pharmaceutical care and insulin staging.
Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.

Locations

Country	Name	City	State
Iraq	College of Pharmacy-University of Sulaimani	Sulaymaniyah

Sponsors (1)

Lead Sponsor	Collaborator
University of Sulaimani

Country where clinical trial is conducted

Iraq, 

References & Publications (5)

Chumney EC, Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. Pharm Pract (Granada). 2006 Jul;4(3):103-9. — View Citation

Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician's guide. 2nd ed. New York: McGraw-Hill, Medical Pub. Division; 2004. 394 p.

Mansour A, Al Douri F. Diabetes in Iraq: Facing the Epidemic. A systematic Review. Wulfenia. 2015;22(3):258.

Saseen JJ, Ripley TL, Bondi D, Burke JM, Cohen LJ, McBane S, McConnell KJ, Sackey B, Sanoski C, Simonyan A, Taylor J, Vande Griend JP. ACCP Clinical Pharmacist Competencies. Pharmacotherapy. 2017 May;37(5):630-636. doi: 10.1002/phar.1923. Epub 2017 May 2. — View Citation

Whittlesea C, Hodson K. Clinical pharmacy and therapeutics. Elsevier 2019.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change of glycated hemoglobin (HbA1c).	HbA1c refers to glycated hemoglobin (A1c) , which identifies average plasma glucose concentration (in %).	Up to 6 months.
Primary	Measurement of Lipid profile (LDL, HDL, cholesterol and triglyceride)	Lipid profile refers to pattern of lipids in the blood (in mg/dL). A lipid profile usually includes the levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and the calculated low-density lipoprotein (LDL) 'cholesterol.	Up to 6 months.
Primary	Measurement of Drug therapy problems (DTP).	Drug therapy problem (DTP) refers to any unwanted incident related to medication therapy that actually or potentially affects the desired goals of treatment.	Up to 6 months.
Primary	Fasting plasma glucose (FPG)	FPG measures the levels of glucose in the plasma (in mg/dL).To assess the effect of insulin on the FPG level.	Up to 6 months.
Secondary	Body Weight.	Body Weight: the amount that a person weighs (in kg), To find out whether the patient is obese or not.	Up to 6 months.